These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 18066039)

  • 21. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Palivizumab in viral respiratory infections].
    Grell L
    Internist (Berl); 2005 Apr; 46(4):474; author reply 474, 476. PubMed ID: 15717184
    [No Abstract]   [Full Text] [Related]  

  • 24. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
    Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
    Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1.
    Chen Y; Luo W; Wu WL; Fang Z; Xia L; Gui X; Chen Y; Chen H; Shih JW; Xia N
    Antiviral Res; 2010 Jul; 87(1):81-4. PubMed ID: 20450935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies.
    Chartrain M; Chu L
    Curr Pharm Biotechnol; 2008 Dec; 9(6):447-67. PubMed ID: 19075685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.
    Yang F; Xiao Y; Lu R; Chen B; Liu F; Wang L; Yao H; Wu N; Wu H
    Emerg Microbes Infect; 2020; 9(1):664-675. PubMed ID: 32193996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.
    Lambour J; Naranjo-Gomez M; Piechaczyk M; Pelegrin M
    Emerg Microbes Infect; 2016 Aug; 5(8):e92. PubMed ID: 27530750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.
    Ku Z; Ye X; Shi J; Wang X; Liu Q; Huang Z
    J Virol; 2015 Dec; 89(23):12084-95. PubMed ID: 26401034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
    Tan Y; Ng Q; Jia Q; Kwang J; He F
    J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics.
    Gilchuk P; Bombardi RG; Erasmus JH; Tan Q; Nargi R; Soto C; Abbink P; Suscovich TJ; Durnell LA; Khandhar A; Archer J; Liang J; Fouch ME; Davidson E; Doranz BJ; Jones T; Larson E; Ertel S; Granger B; Fuerte-Stone J; Roy V; Broge T; Linnekin TC; Linde CH; Gorman MJ; Nkolola J; Alter G; Reed SG; Barouch DH; Diamond MS; Crowe JE; Van Hoeven N; Thackray LB; Carnahan RH
    Nat Biomed Eng; 2020 Nov; 4(11):1030-1043. PubMed ID: 32747832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus.
    Jin J; Simmons G
    Viruses; 2019 Mar; 11(4):. PubMed ID: 30925717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MERS-CoV spike protein: a key target for antivirals.
    Du L; Yang Y; Zhou Y; Lu L; Li F; Jiang S
    Expert Opin Ther Targets; 2017 Feb; 21(2):131-143. PubMed ID: 27936982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
    Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
    Nachbagauer R; Shore D; Yang H; Johnson SK; Gabbard JD; Tompkins SM; Wrammert J; Wilson PC; Stevens J; Ahmed R; Krammer F; Ellebedy AH
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mining the tree of life: Host defense peptides as antiviral therapeutics.
    Shartouny JR; Jacob J
    Semin Cell Dev Biol; 2019 Apr; 88():147-155. PubMed ID: 29524585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.
    Yang X; Qi J; Peng R; Dai L; Gould EA; Gao GF; Tien P
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Memory B Cells Producing Potent Cross-Neutralizing Antibodies against Human Parechovirus: Implications for Prevalence, Treatment, and Diagnosis.
    Westerhuis BM; Benschop KS; Koen G; Claassen YB; Wagner K; Bakker AQ; Wolthers KC; Beaumont T
    J Virol; 2015 Aug; 89(15):7457-64. PubMed ID: 25948742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift.
    Lambkin R; McLain L; Jones SE; Aldridge SL; Dimmock NJ
    J Gen Virol; 1994 Dec; 75 ( Pt 12)():3493-502. PubMed ID: 7527838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.